Cargando…
Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study
A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent use...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608704/ https://www.ncbi.nlm.nih.gov/pubmed/37888075 http://dx.doi.org/10.3390/jpm13101464 |
_version_ | 1785127843338911744 |
---|---|
author | Frandon, Julien Loffroy, Romaric Marcelin, Clement Vernhet-Kovacsik, Hélène Greffier, Joel Dabli, Djamel Sammoud, Skander Marek, Pierre Chevallier, Olivier Beregi, Jean-Paul Rousseau, Hervé |
author_facet | Frandon, Julien Loffroy, Romaric Marcelin, Clement Vernhet-Kovacsik, Hélène Greffier, Joel Dabli, Djamel Sammoud, Skander Marek, Pierre Chevallier, Olivier Beregi, Jean-Paul Rousseau, Hervé |
author_sort | Frandon, Julien |
collection | PubMed |
description | A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent used to treat peripheral vascular anomalies was left to the investigator’s discretion. Patients for whom at least one Prestige coil was used were included in Series 1. All other patients were included in Series 2. Efficacy and safety were evaluated. Patients were followed up for one month. In total, 220 patients were included, 110 in each series. Patients included 149 men (67.7%) and 71 women (32.3%), with a median age of 62.5 years (IQR: 35.8–73). Patient ages were similar in the two series. Complete occlusion of the targeted vessel was reported in 96.4% (n = 106/110) of patients in Series 1 and in 99.7% (n = 109/110) in Series 2. Four patients experienced non-serious adverse events (1.8%, n = 4/220): one experienced back pain and one vomiting in Series 1; one patient had off-target embolization and one a puncture site hematoma in Series 2. Sixteen patients (7.2%, n = 16/220) were lost to follow up. Improvement in the patient’s general state at one month was reported in 79.0% (n = 83/105) of patients in Series 1 and in 74.7% (n = 74/99) in Series 2. Ten deaths occurred, five in Series 1 (4.8%, n = 5/105) and five in Series 2 (5.1%, n = 5/99). These deaths all concerned critically ill patients embolized for emergent arterial bleeding. In conclusion, the 1-month follow-up showed that Prestige coils, alone or in combination, are efficient and safe. |
format | Online Article Text |
id | pubmed-10608704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106087042023-10-28 Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study Frandon, Julien Loffroy, Romaric Marcelin, Clement Vernhet-Kovacsik, Hélène Greffier, Joel Dabli, Djamel Sammoud, Skander Marek, Pierre Chevallier, Olivier Beregi, Jean-Paul Rousseau, Hervé J Pers Med Article A wide variety of coils are available for vascular embolization. This study aimed to evaluate the safety and efficacy of a new Prestige coil. We carried out retrospective analysis of a multicenter’s registry data collected between February 2022 and November 2022. The choice of embolization agent used to treat peripheral vascular anomalies was left to the investigator’s discretion. Patients for whom at least one Prestige coil was used were included in Series 1. All other patients were included in Series 2. Efficacy and safety were evaluated. Patients were followed up for one month. In total, 220 patients were included, 110 in each series. Patients included 149 men (67.7%) and 71 women (32.3%), with a median age of 62.5 years (IQR: 35.8–73). Patient ages were similar in the two series. Complete occlusion of the targeted vessel was reported in 96.4% (n = 106/110) of patients in Series 1 and in 99.7% (n = 109/110) in Series 2. Four patients experienced non-serious adverse events (1.8%, n = 4/220): one experienced back pain and one vomiting in Series 1; one patient had off-target embolization and one a puncture site hematoma in Series 2. Sixteen patients (7.2%, n = 16/220) were lost to follow up. Improvement in the patient’s general state at one month was reported in 79.0% (n = 83/105) of patients in Series 1 and in 74.7% (n = 74/99) in Series 2. Ten deaths occurred, five in Series 1 (4.8%, n = 5/105) and five in Series 2 (5.1%, n = 5/99). These deaths all concerned critically ill patients embolized for emergent arterial bleeding. In conclusion, the 1-month follow-up showed that Prestige coils, alone or in combination, are efficient and safe. MDPI 2023-10-05 /pmc/articles/PMC10608704/ /pubmed/37888075 http://dx.doi.org/10.3390/jpm13101464 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frandon, Julien Loffroy, Romaric Marcelin, Clement Vernhet-Kovacsik, Hélène Greffier, Joel Dabli, Djamel Sammoud, Skander Marek, Pierre Chevallier, Olivier Beregi, Jean-Paul Rousseau, Hervé Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title | Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title_full | Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title_fullStr | Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title_full_unstemmed | Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title_short | Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study |
title_sort | safety and efficacy of prestige coils for embolization of vascular abnormalities: the embo-prestige study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608704/ https://www.ncbi.nlm.nih.gov/pubmed/37888075 http://dx.doi.org/10.3390/jpm13101464 |
work_keys_str_mv | AT frandonjulien safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT loffroyromaric safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT marcelinclement safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT vernhetkovacsikhelene safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT greffierjoel safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT dablidjamel safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT sammoudskander safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT marekpierre safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT chevallierolivier safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT beregijeanpaul safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy AT rousseauherve safetyandefficacyofprestigecoilsforembolizationofvascularabnormalitiestheemboprestigestudy |